By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ImmunoGen, Inc. 

128 Sidney Street

Cambridge  Massachusetts  02139-4239  U.S.A.
Phone: 617-995-2500 Fax: 617-995-2510


SEARCH JOBS




Collaborations

GlaxoSmithKline (North Carolina) 

Raven Biotechnologies, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.

Medarex, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.





Company News
ImmunoGen (IMGN) Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia 6/26/2017 9:01:47 AM
ImmunoGen (IMGN) And Sanofi (SNY) Amend License Agreements 5/30/2017 8:51:35 AM
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen (IMGN) 5/24/2017 8:47:20 AM
ImmunoGen (IMGN) Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting 5/18/2017 8:41:34 AM
ImmunoGen (IMGN) Reports Recent Progress And First Quarter 2017 Operating Results 5/5/2017 6:12:22 AM
ImmunoGen (IMGN) Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer 5/1/2017 7:26:51 AM
ImmunoGen (IMGN) Announces Conference Call To Discuss Its First Quarter 2017 Financial Results 4/21/2017 7:40:34 AM
ImmunoGen (IMGN) Presents Phase I Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting 3/13/2017 6:26:27 AM
ImmunoGen (IMGN) Announces Presentations At AACR Annual Meeting 3/2/2017 10:50:39 AM
Why ImmunoGen (IMGN) Investors are Waiting on Bated Breath to Move "FORWARD" 2/22/2017 5:42:04 AM
12345678910...
//-->